1. Antibodies to Both Ro52 and Ro60 for Identifying Sjögren's Syndrome Patients Best Suited for Clinical Trials of Disease‐Modifying Therapies. Issue 9 (10th June 2022) Authors: Armağan, Berkan; Robinson, Susan A.; Bazoberry, Adriana; Perin, Jamie; Grader‐Beck, Thomas; Akpek, Esen K.; Kim, Jean; Baer, Alan N. Journal: Arthritis care & research Issue: Volume 74:Issue 9(2022) Page Start: 1559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0172 ANTIBODIES TO BOTH RO52 AND RO60 DEFINE A SUBSET OF SJÖGREN'S MOST SUITABLE FOR CLINICAL TRIALS OF AGENTS TARGETING LYMPHOPROLIFERATIONS. (June 2019) Authors: Armagan, Berkan; Robinson, Susan; Bazoberry, Adriana; Grader-Beck, Thomas; Baer, Alan Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 1160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗